RxDoctor Payments Data

Tramaine Davis, MD

Family Medicine · Bowie, MDNPI 1730490186

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $32,415 of the $42,815 with a category attached, or 75.7%. Gilead accounts for 97.5% of it on its own, with 5 other manufacturers making up the rest. Among family medicine clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$42,815in general payments, 2019–2025

Across 152 payments — averaging $281.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$42K
  • Viiv Healthcare Company$788
  • Merck$180
  • Johnson & Johnson$44
  • Theratechnologies Inc.$42
  • GSK$21

What the payments were for

  • Consulting fees$2,7506%
  • Speaking & faculty fees$32,41576%
  • Travel & lodging$4,26710%
  • Food & beverage$3,3728%
  • Education$110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead100$41,740
Viiv Healthcare Company36$788
Merck11$180
Johnson & Johnson2$44
Theratechnologies Inc.2$42
GSK1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,815 in reported general payments places this provider in the 95th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$7,412
Medicare patients
20
Services billed
841

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala128$525,620
GenvoyaElviteg/Cob/Emtri/Tenof Alafen25$112,571
TriumeqAbacavir/Dolutegravir/Lamivudi18$69,915
PrezcobixDarunavir/Cobicistat17$45,503
Atovaquone11$2,818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$41,740$638,191153 claims
Viiv Healthcare CompanyTriumeq$788$69,91518 claims
Johnson & JohnsonPrezcobix$44$45,50317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Bowie

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →